WWC
IRWD icon

Waypoint Wealth Counsel’s Ironwood Pharmaceuticals IRWD Stock Holding History

Waypoint Wealth Counsel’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,999
Closed -$42.1K – 189
2026
Q1 		$42.1K Sell
11,999
-504
-4% -$2.07K 0.02% 225
2025
Q4 		$42.1K Sell
12,503
-155
-1% -$403 0.02% 282
2025
Q3 		$16.6K Buy
+12,658
New +$13.1K 0.01% 267

Other funds holding IRWD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Waypoint Wealth Counsel's IRWD Position: Q2 2026 in Review

Waypoint Wealth Counsel sold out of Ironwood Pharmaceuticals (IRWD) in Q2 2026, closing a stake of 11,999 shares — an estimated $42.1K sold.

Waypoint Wealth Counsel first reported a position in IRWD in Q3 2025 and held it in 3 quarters. The position peaked at $42.1K in Q4 2025. 212 funds tracked by Wall St. Rank hold IRWD as of Q2 2026.

  • Waypoint Wealth Counsel reported no remaining Ironwood Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Waypoint Wealth Counsel sold 11,999 Ironwood Pharmaceuticals shares in Q2 2026, an estimated $42.1K.
  • Waypoint Wealth Counsel first reported a position in Ironwood Pharmaceuticals in Q3 2025 and held it in 3 quarters.
  • Waypoint Wealth Counsel's Ironwood Pharmaceuticals position peaked at $42.1K in Q4 2025.
  • 212 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2026.

Based on Waypoint Wealth Counsel's 13F filing for Q2 2026, filed 4 Aug 2026.